Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01478256 · ClinicalTrials.gov registry record · Phase 4

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

A Phase 4 study of Blepharitis, sponsored by John, George, M.D..

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT01478256 is a Phase 4 study of Blepharitis that has completed, run by John, George, M.D.. The registered enrollment target is 30 participants, below the 55-participant average among 6 other Blepharitis trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01478256, a Phase 4 study of Blepharitis, has completed, sponsored by John, George, M.D..

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study looks at the improvements in signs and symptoms in patients with inflammation of the lids, blepharitis, using two different FDA approved topical antibiotic agents, Besifloxocin and Erythromycin. It also evaluates the bacterial cultures in these patients for microbiologic evidence of improvement.

Conditions Studied

Interventions

  • DRUG Erythromycin
  • DRUG Besifloxocin

Study Locations (1)

Kentucky

  • George John, M.D. - Louisville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-08
Est. Completion 2011-10
Phase Phase 4

Sponsor

John, George, M.D.

1 total trials

What the Registry Record Tells You About NCT01478256

The ClinicalTrials.gov registry entry for NCT01478256 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55-participant average among 6 other Blepharitis trials with a reported enrollment target (45% lower). The listed sponsor is John, George, M.D., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Blepharitis appearing as the primary indexed condition, and to 2 interventions - of which Erythromycin is the first listed.

NCT01478256 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT01478256 about?

NCT01478256 is a clinical study titled "Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis". This study looks at the improvements in signs and symptoms in patients with inflammation of the lids, blepharitis, using two different FDA approved topical antibiotic agents, Besifloxocin and Erythromycin. It also evaluates the bacterial cultures in these patients for microbiologic evidence of impro...

What is the current status of trial NCT01478256?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2011-08. Estimated completion is 2011-10.

What conditions does trial NCT01478256 study?

This clinical trial studies the following conditions: Blepharitis.

What interventions are being tested in trial NCT01478256?

The interventions under investigation include: Erythromycin (DRUG), Besifloxocin (DRUG).

Who is sponsoring clinical trial NCT01478256?

This trial is sponsored by John, George, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01478256 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blepharitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.